Pierre Beaurang, Ph.D., is the CEO of Nitrase Therapeutics. He joined Nitrase Therapeutics from Nurix Therapeutics, where he was most recently the company’s Chief Business Officer. During his tenure at Nurix, he was responsible for establishing three transformational collaborations, namely with Celgene (now BMS), Gilead and Sanofi, which resulted in over $300 million in near term revenues and more than $5 billion in potential milestone payments. He also was part of the leadership team that took Nurix public in a $238 million IPO and helped advanced several programs into clinical testing. Prior to joining Nurix, Dr. Beaurang was part of the founding team of Five Prime Therapeutics, a biotechnology company developing immune modulators and precision therapies for solid tumor cancers, where he negotiated a number of major collaborations with global pharmaceutical firms, including with GlaxoSmithKline, UCB, and Bristol Myers Squibb, helping secure an aggregate $270 million in near term revenues and more than $2.4 billion in potential milestone payments.
Dr. Beaurang holds a B.A. in Biology and an M.A. in Biotechnology from Boston University, and a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.